Skip to main content
Explore URMC

Deepak Madhao Sahasrabudhe, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-9319

Office: (585) 275-5823

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Hospital Medicine


There are general principles of cancer care that have withstood the test of time. However, scientific and technologic advances are being made rapidly. As an oncologist, I always remember that a patient is at the end of every stethoscope, robot, sequencing machine and so on.

I chose this field because it is most interdisciplinary and dynamic – plus, I work with a team of outstanding colleagues. I have a special interest in what was once called tumor immunology, now referred to as immuno-oncology.

Conditions I Treat

- Melanoma
- Prostate cancer
- Urinary cancer
- Bladder cancer
- Kidney cancer
- Testicular cancer
- Penile cancer
- Sarcomas
- Rare cancers such as Merkel cell carcinoma and Kaposi's sarcoma

Professional Background

Deepak Sahasrabudhe is a Professor of Medicine in the Division of Hematology/Oncology at the James P. Wilmot Cancer Center at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Dr. Sahasrabudhe received his training at Albany Medical Center Hospital in Albany, New York and the University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Dr. Sahasrabudhe is a key teaching faculty member in the Hematology/Oncology Fellowship Program. He has mentored several fellows over the last 17 years.

Dr. Sahasrabudhe's clinical research interest is in urologic malignancies. He also sees patients with melanomas and sarcomas.

Dr. Sahasrabudhe is a member of many national professional organizations including the American College of Physicians, the American Association for Cancer Research, and the American Society of Clinical Oncology.



MD | University of Bombay, Lokmanya Tilak (India)

Post-doctoral Training & Residency

07/01/1982 - 06/01/1986
Fellowship at University of Rochester Medical Center

07/01/1979 - 06/30/1982
Fellowship in Hematology & Oncology at University of North Carolina Healthcare-CRNA verifs

07/01/1977 - 06/30/1979
Residency in Internal Medicine at Albany Medical Center Hospital

07/01/1976 - 06/30/1977
Internship in Internal Medicine at Albany Medical Center Hospital

VIEW ALL expand_more


Gitelman Award
Sponsor: Gilda's Club
Location: Rochester, NY

Clinical Trials

An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies

Lead Researcher: Deepak Madhao Sahasrabudhe MD

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.

View Study Details

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

Lead Researcher: Deepak Madhao Sahasrabudhe MD

This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the usual treatment may make it work better. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known how well the combination of cabozantinib and nivolumab after initial treatment with ipilimumab and nivolumab works in treating patients with renal cell cancer that has spread to other parts of the body.

View Study Details


Journal Articles

Dineen M, Hansen E, Guancial E, Sievert L, Sahasrabudhe D. "Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature." Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.. 2018 Jun; 24(4):314-318. Epub 2017 Mar 29.

Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB, . "Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2018 May 20; 36(15):1505-1512. Epub 2018 Apr 04.

Pan C, Singh S, Sahasrabudhe DM, Chakkalakal JV, Krolewski JJ, Nastiuk KL. "TGF? Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice." Endocrinology.. 2016 Nov; 157(11):4461-4472. Epub 2016 Sep 09.

Books & Chapters

Chapter Title: Bone Tumors
Book Title: Clinical Oncology, 8th Edition
Author List: Rosier, RN; O'Keefe, RJ; Sahasrabudhe, DM
Edited By: Rubin P.
Published By: W.B. Saunders Company, Harcourt Brace Jovanovich, Inc 2001 in Philadelphia PA

Chapter Title: Soft Tissue Sarcoma
Book Title: Clinical Oncology, 8th Edition
Author List: Spiro, IJ; Suit, HD; Rosier, RN; Sahasrabudhe, DM
Edited By: Rubin P.
Published By: W.B. Saunders Company, Harcourt Brace Jovanovich Inc 2001 in Philadelphia PA